Cellular cancer markers
著者
書誌事項
Cellular cancer markers
(Contemporary biomedicine)
Humana Press, c1995
大学図書館所蔵 全8件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
In Cellular Cancer Markers leading pathologists and physicians review today's most promising cellular cancer markers, an important emerging class of prognostic markers that can be used in the clinical evaluation of cancer patients. The markers reviewed have been chosen because they are biologically relevant to the growth of cells and possess an accurate and reproducible assay for detection. They also are predictors of tumor behavior, are useful in making clinical decisions, and are cost effective.
Cellular Cancer Markers provides a status report for markers of tumor cell activation, proliferation, and longevity that makes possible an informed judgment regarding the value of many newly proposed tumor markers. It also offers insight into the latest approaches to diagnosing cancer and an appreciation of how these marker-based tests can clarify the prognosis of cancer.
目次
Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer. ras Proto-Oncogene Activation in Human Malignancy. C-myc as a Tumor Marker for Primary Human Cancers. p53 in Human Cancer. Oncogenes and Tumor Suppressor Genes in Gynecological Malignancies. Genetic Alterations in Colon Cancer. Genetic Changes in Breast Cancer. Genetic Alterations in Lung Cancer. Wilms Tumor-Susceptibility Loci. Non-Hodgkin's Lymphomas. Phenotype Expression of Hodgkin's Disease: Biologic, Immunologic, and Functional Properties. Melanoma Markers. Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma. P-Glycoproteins in Tumors. Genetically Engineered Antitumor Monoclonal Antibodies. Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of c-AMP Dependent Protein Kinase. Summary and Perspective: Assessing Test Effectiveness-The Identification of Good Tumor Markers. Index.
「Nielsen BookData」 より